Tackling resistance: emerging antimalarials and new parasite targets in the era of elimination.

ABSTRACT: Malaria remains a significant contributor to global human mortality, and roughly half the world's population is at risk for infection with Plasmodium spp. parasites. Aggressive control measures have reduced the global prevalence of malaria significantly over the past decade. However, resistance to available antimalarials continues to spread, including resistance to the widely used artemisinin-based combination therapies. Novel antimalarial compounds and therapeutic targets are greatly needed. This review will briefly discuss several promising current antimalarial development projects, including artefenomel, ferroquine, cipargamin, SJ733, KAF156, MMV048, and tafenoquine. In addition, we describe recent large-scale genetic and resistance screens that have been instrumental in target discover

SUBMITTER: Mathews ES 

PROVIDER: S-EPMC6073090 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature